Fundamental dimension Equity attribute | ORBNPeer $40.30▲+0.75% Cap $99.70MP/E 32.8x QuantScore44/100 | BEOBLeader $62.300.00% Cap $151.6MP/E 9.4x QuantScore66/100 | CZBCPeer $16.000.00% Cap $89.99MP/E 43.3x QuantScore39/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
84/100 |
45/100 |
91/100 |
Valuation Multiples, PEG & DCF upside | 40/100 | 100/100 | 12/100 |
Health Piotroski, Altman Z, leverage & liquidity | 24/100 | 65/100 | 25/100 |
Growth Revenue / earnings growth & margins | 27/100 | 52/100 | 25/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | 32.8x | 9.4x | 43.3x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | 21.7x | 6.8x | 43.4x |
Price / Sales | 3.2x | 2.6x | 2.6x |
Price / Free Cash Flow | — | 10.4x | — |
PEG ratio | -13.76 | 0.09 | -2.21 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 4 / 9 | 3 / 9 | 4 / 9 |
Altman Z-Score | -0.57 (Distress) | 12.90 (Safe) | 0.23 (Distress) |
Total debt / equity | 0.32 | 0.08 | 0.26 |
Quick ratio | 0.1x | 95.9x | 0.8x |
Interest coverage | 0.5x | 3.7x | 0.5x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | -8.1% | +12.2% | -13.8% |
Net income growth YoY | -5.0% | -2.0% | -26.2% |
Gross margin (TTM) | 75.0% | 90.2% | 85.0% |
Operating margin (FY) | 11.9% | 36.2% | 8.0% |
FCF margin (FY) | 9.8% | 24.7% | 22.1% |
5. Trailing price performancePrice change over period |
1M return | +0.8% | -3.0% | +0.4% |
3M return | -0.4% | +6.0% | +3.2% |
6M return | +49.3% | +13.5% | +18.1% |
Year to date | +54.3% | +15.4% | +57.6% |
1Y return | +97.5% | +22.2% | +64.1% |
3Y return | +78.7% | +140.1% | +33.3% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $25.81 -35.9% premium | $112.45 +80.5% upside | $9.88 -38.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |